Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Subdominant SARS-CoV-2 epitopes key to understanding emerging variants

Researchers in the UK have conducted a study showing the importance of considering subdominant epitopes within severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) when investigating neutralizing antibodies that target the virus.

7 Feb 2021

How does SARS-CoV-2 infect the pancreas?

To understand how SARS-CoV-2 infects the pancreas and investigate its effects, a team of researchers used the human iPSC (induced pluripotent stem cells)-derived pancreatic cultures and analyzed the post-infection cellular and molecular changes.

5 Feb 2021

AI model aids early detection of severe COVID-19 infection in children

Children have been less impacted by COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) than adults. But some children diagnosed with SARS-CoV-2 have experienced severe illnesses, including Multisystem Inflammatory Syndrome (MIS-C) and respiratory failure; nearly 80% of children with MIS-C become critically ill with a 2 to 4% mortality rate.

5 Feb 2021

Research shows intestinal parasite infestations reduce COVID-19 severity

Now, new research out of Mekelle, Ethiopia, examines the role of parasitic infestation on the prognosis of COVID-19. The research paper, which appears on the preprint server medRxiv, shows that intestinal parasitosis is protective against severe COVID-19.

4 Feb 2021

Greater muscle strength associated with lower risk of COVID-19 hospitalization

A new preprint research paper posted to the medRxiv* server discusses the results of a study exploring the relationship between increased muscle strength and hospitalization for severe COVID-19.

4 Feb 2021

Alpaca nanobodies neutralize SARS-CoV-2 in vitro

A new preprint research paper posted to the bioRxiv server reports the development of highly effective neutralizing nanobodies targeting the viral receptor-binding domain (RBD), thus disrupting its engagement with the host cell angiotensin-converting enzyme 2 (ACE2) receptor.

4 Feb 2021

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Among these is the B.1.1.7 SARS-CoV-2 variant, with its characteristic N501Y mutation. A new preprint on the bioRxiv server reports the impact of this mutation on CD4 T cell responses, including antigen presentation on cells expressing Major Histocompatibility Complex (MHC) class II molecules.

4 Feb 2021

COVID-19 vaccination alone may not end the pandemic

A simulation-based study conducted at the Miami University, USA, has revealed that vaccination of the general population against coronavirus disease 2019 (COVID-19) alone is not sufficient to control the pandemic, given the current availability and implementation strategies.

4 Feb 2021

ZyCoV-D SARS-CoV-2 DNA vaccine shows robust immunogenicity and protective efficacy in Rhesus macaquesys

A team of scientists from India has recently tested the efficacy and immunogenicity of two different concentrations of a plasmid DNA-based vaccine candidate ZyCoV-D. The findings reveal that the vaccine candidate administered via Needle Free Injection System (NFIS) can significantly induce the production of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG and neutralizing antibodies for a prolonged period.

4 Feb 2021

Seasonal flu shots reduce COVID-19 symptoms in children

Researchers from the University of Missouri School of Medicine have discovered that children who receive a seasonal flu shot are less likely to suffer symptoms from a COVID-19 infection. The finding comes from a review of more than 900 children diagnosed with COVID-19 in 2020.

4 Feb 2021

Phase I/II trial findings support use of CoronaVac vaccine in older individuals

Researchers in China have reported phase I/II clinical trial findings showing that the vaccine candidate CoronaVac is well tolerated among older individuals and effectively generates antibody responses against severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).

4 Feb 2021

New study supports UK’s delay of the SARS-CoV-2 Pfizer vaccine second dose

After reanalyzing data from 500,000 people in Israel who received the Pfizer vaccine, researchers suggest a single dose provides sufficient immunity after about 21 days, thus providing support for the UK’s decision to delay the second dose to 12 weeks.

4 Feb 2021

Researchers develop thermostable RNA vaccine delivery platform

A new study describes the production of a new RNA vaccine delivery system that promises greater ease of storage and distribution. This could help boost vaccination rates in regions without adequate infrastructure for low-temperature storage.

4 Feb 2021

South African SARS-CoV-2 variant neutralized by two Chinese vaccines in case study

A new study offers some reassuring findings, reporting the successful neutralization of the South African SARS-CoV-2 variant of concern (VOC) 501Y.V2 by two vaccines developed in China.

4 Feb 2021

Monoclonal antibodies against SARS-CoV-2 spike's N-terminal prove highly protective in vivo

A new study server reports highly protective neutralizing monoclonal antibodies against the SARS-CoV-2.

4 Feb 2021

SARS-CoV-2 has developed worrying new mutation in UK

Over the past few months, surging cases have been reported due to new fast-spreading variants. Now, Public Health England (PHE) investigates cases of COVID-19 with worrying new genetic changes. The E484K mutation, which could allow SARS-CoV-2 escape antibody protection, was seen in a small group of cases in some regions of the country.

4 Feb 2021

Predicting future mamalian hosts of SARS-CoV-2

Researchers at the Beijing Computational Science Research Center and Peking University analyzed sequences of the angiotensin-converting enzyme 2 (ACE2) proteins from 16 mammals and predicted the structures of ACE2- receptor-binding domain (RBD) complexes.

4 Feb 2021

Russia's Sputnik V COVID-19 shown to have 91.6 percent efficacy

The phase 3 human trial is the last stage of clinical evaluation, showing how effective and safe a drug or vaccine is. In this case, the Gam- Sputnik V showed a consistent strong protective effect across all participant age groups.

3 Feb 2021

Hematological findings in Amazonian patients with COVID-19

To discriminate between patients with severe and non-severe COVID-19 quickly, researchers from Peru looked for prognostic signatures in the blood samples of COVID-19 patients. Virgilio E. Failoc-Rojas et al. examined laboratory results and clinical prognosis of COVID-19 patients from a hospital in the Peruvian Amazon.

3 Feb 2021

Survey finds 41% of United States residents unwilling to receive a COVID-19 vaccine

A cross-sectional online survey conducted by the scientists of Johns Hopkins Bloomberg School of Public Health, USA, has revealed that about 41% of US residents are unwilling to receive a coronavirus disease 2019 (COVID-19) vaccine due to concern over vaccine safety and efficacy. Moreover, there are sub-group variations in willingness to receive a COVID-19 vaccine

3 Feb 2021